Research Progress of Immune Checkpoint Inhibitors Combined with Anti-Angiogenic Drugs in Treatment of Advanced Non-Small Cell Lung Cancer
10.3971/j.issn.1000-8578.2025.24.1280
- VernacularTitle:免疫检查点抑制剂联合抗血管生成药物治疗晚期非小细胞肺癌的研究进展
- Author:
Aiju ZENG
1
;
Daiyuan MA
1
Author Information
1. Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, China;School of Clinical Medicine, North Sichuan Medical University, Nanchong 637000, China.
- Publication Type:REVIEWS
- Keywords:
Non-small cell lung cancer;
Immune checkpoint inhibitors;
Anti-angiogenic drugs
- From:
Cancer Research on Prevention and Treatment
2025;52(6):527-532
- CountryChina
- Language:Chinese
-
Abstract:
The use of immune checkpoint inhibitors (ICIs) improves the prognosis of patients with advanced non-small cell lung cancer (NSCLC). However, some patients still fail to benefit from them. In recent years, studies have demonstrated that the combination of antiangiogenic agents with ICIs can enhance the antitumor effect, and guidelines at home and abroad have suggested that the combination of ICIs with antiangiogenic regimens can be used in patients with advanced NSCLC. Therefore, the mechanism of action and the latest clinical studies on the combination of ICIs and anti-angiogenic drugs in the treatment of advanced NSCLC were reviewed in this article to provide reference for treating advanced NSCLC.
